2nd US biosimilar market report released by Samsung Bioepis

12 July 2023

South Korean biosimilars company Samsung Bioepis has now released the second edition of its Biosimilar Market Report, which explores latest market trends for all biosimilars commercially available in the USA.

The second quarterly report details the recent price trends of all molecules for launched biosimilars including updated 2023 third quarter ASP trends and WAC trends of adalimumab biosimilars.

“So far in 2023, we have seen the start of biosimilars being launched within pharmacy benefits. This is the start of new beginning for biosimilars in the United States,” said Tom Newcomer, vice president, head of market access, US, at Samsung Bioepis. “We hope Samsung Bioepis Biosimilar Market Report brings value to healthcare stakeholders involved in the decision-making process, providing an up-to-date perspective on the US biosimilar landscape,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK